FIRST-INHUMAN STUDY OF SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF IRAK1/4 INHIBITOR R835 IN HEALTHY SUBJECTS

被引：2

作者：

Yan, L. ^{[1
]}

Tong, S. ^{[1
]}

Absalom, A. ^{[2
]}

Daas, I. D. ^{[3
]}

Park, G. ^{[1
]}

Taylor, V. ^{[1
]}

Chow, D. ^{[1
]}

Lee, M. ^{[1
]}

Zheng, H. ^{[1
]}

Chow, A. ^{[1
]}

机构：

[1] Rigel Pharmaceut Inc, San Francisco, CA USA

[2] Univ Med Ctr Groningen, Groningen, Netherlands

[3] QPS Netherlands BV, Groningen, Netherlands

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2020年 / 79卷

关键词：

D O I：

10.1136/annrheumdis-2020-eular.4590

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

THU0219

引用

页码：332 / 332

页数：1

共 50 条

[21] The Pharmacokinetics, Pharmacodynamics, and Safety of Baricitinib, an Oral JAK 1/2 Inhibitor, in Healthy Volunteers
Shi, Jack G.
Chen, Xuejun
Lee, Fiona
Emm, Thomas
Scherle, Peggy A.
Lo, Yvonne
Punwani, Naresh
Williams, William V.
Yeleswaram, Swamy
JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 54 (12): : 1354 - 1361
[22] FIRST-IN-HUMAN STUDY OF GS-5718, AN ORAL IRAK-4 INHIBITOR, IN HEALTHY SUBJECTS: PHARMACOKINETICS, SAFETY, TOLERABILITY, AND ASSESSMENT OF EFFECT OF FOOD AND ACID REDUCING AGENTS ON EXPOSURE
Anderson, K.
Hsueh, C. H.
Gurtovaya, O.
Mathur, A.
Taylor, J.
Serone, A.
Othman, A. A.
ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 581 - 581
[23] Safety, pharmacokinetics, and pharmacodynamics of ART-648, a PDE4 inhibitor in healthy subjects: A randomized, placebo-controlled phase I study
Tanaka, Akira
Nagabukuro, Hiroshi
Kuniyeda, Kanako
Ando, Haruhi
Higashi, Toshinori
Wakuda, Hirokazu
Otani, Naoyuki
Kudo, Hideo
Kuranari, Masae
Furuie, Hidetoshi
Uemura, Naoto
CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2024, 17 (10):
[24] Pharmacokinetics, pharmacodynamics, safety, and tolerability of pradigastat, a novel diacylglycerol acyltransferase 1 inhibitor in overweight or obese, but otherwise healthy human subjects
Meyers, Charles D.
Amer, Ahmed
Majumdar, Tapan
Chen, Jin
JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 55 (09): : 1031 - 1041
[25] Pharmacokinetics, Pharmacodynamics and Safety of Febuxostat, a Non-Purine Selective Inhibitor of Xanthine Oxidase, in a Dose Escalation Study in Healthy Subjects
Reza Khosravan
Brian A. Grabowski
Jing-Tao Wu
Nancy Joseph-Ridge
Laurent Vernillet
Clinical Pharmacokinetics, 2006, 45 : 821 - 841
[26] Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects
Khosravan, Reza
Grabowski, Brian A.
Wu, Jing-Tao
Joseph-Ridge, Nancy
Vernillet, Laurent
CLINICAL PHARMACOKINETICS, 2006, 45 (08) : 821 - 841
[27] Safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06650833, a selective interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, in single and multiple ascending dose randomized phase 1 studies in healthy subjects
Spencer I. Danto
Negin Shojaee
Ravi Shankar P. Singh
Cheryl Li
Steven A. Gilbert
Zorayr Manukyan
Iain Kilty
Arthritis Research & Therapy, 21
[28] Safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06650833, a selective interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, in single and multiple ascending dose randomized phase 1 studies in healthy subjects
Danto, Spencer, I
Shojaee, Negin
Singh, Ravi Shankar P.
Li, Cheryl
Gilbert, Steven A.
Manukyan, Zorayr
Kilty, Iain
ARTHRITIS RESEARCH & THERAPY, 2019, 21 (01)
[29] MIV-711, a Highly Selective Cathepsin K Inhibitor, First in Man Study - Safety, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Oral Doses in Healthy Subjects
Grabowska, Urszula
Jerling, Markus
Bottiger, Disa
Larsson, Torbjorn
Danielson, Kerstin
Lindstrom, Erik
Edenius, Charlotte
JOURNAL OF BONE AND MINERAL RESEARCH, 2013, 28
[30] Phase 1 Study of the Safety, Pharmacokinetics and Pharmacodynamics of Teneligliptin, a New DPP-IV Inhibitor, in Healthy Volunteers
Kumagai, Yuji
Fujita, Tomoe
Kawaguchi, Atsuhiro
Hayashi, Yoshiharu
Kondou, Kazuoki
DIABETES, 2010, 59 : A193 - A193

← 1 2 3 4 5 →